Hepatocellular Carcinoma (HCC)
Conditions
Keywords
HCC, Sonazoid, Ultrasonography, Screening
Brief summary
B-mode ultrasonography (B-US), a standard method of surveillance of hepatocellular carcinoma (HCC), has a fair sensitivity of 63% in detecting early stage HCC. Sonazoid, a contrast agent for ultrasonography, has reported to have superior sensitivity in detecting focal liver lesion since it has ability of Kupffer phase imaging as well as vascular phase imaging. So our aim is to compare the detection rate of early stage HCC and false referral rate of HCC between B-mode US and Sonazoid-enhanced ultrasonography (S-US) within the same prospective data group. Our hypothesis is that S-US has superior detection rate of early stage HCC (5%) than that of B-mode US (3%).
Interventions
OTHERSonazoid-enhanced ultrasonography
Sonazoid (perflubutane) \[GE healthcare\]
Sponsors
GE Healthcare
Yonsei University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient 20 years old or older, 2. Patient at high risk of HCC and is supposed to take ultrasonography, 3. Patient who has no suspicious HCC on previous examinations or patient who undergoes the first surveillance, 4. Patient who has liver cirrhosis proven by one of the following methods-liver biopsy (METAVIR score 4), identification of esophageal or gastric varix by endoscopically or radiologically, surface nodularity on ultrasonography, CT or MRI, platelet count less than 100,000/mm3, serum albumin less than 3.5 g/dl, or prothrombin time higher than 1.3 INR, 5. Patient without contraindication for sonazoid, 6. Patient willing to sign the informed consent
Exclusion criteria
1. Patient on pregnancy or breast feeding, 2. Patient with allergy to egg, 3. Patient with left-to-right shunt, respiratory insufficiency, or severe pulmonary hypertension, 4. Patient with history of HCC, 5. Patient with history of malignancy other than HCC -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| False referral rate of HCC | 30±30 days after S-US if there is one or more suspicious HCC detected on S-US, or 180±30 days after S-US if there is no suspicious HCC detected on S-US | False referral rate of HCC = |
| Detection rate of early stage HCC | 30±30 days after S-US if there is one or more suspicious HCC detected on S-US, or 180±30 days after S-US if there is no suspicious HCC detected on S-US | Detection rate of early-stage HCC = (Number of confirmed early-stage HCC detected by a given modality) / (Total number of patients enrolled) x100 |
Countries
South Korea
Outcome results
None listed